Shares of Cipla Ltd ended 1.5% higher on 11th December, after the company announced on Wednesday (11th December) the launch of Yurpeak (tirzepatide) in India. Yurpeak is a once-weekly injectable therapy for managing obesity and type 2 diabetes, two of the country’s most pressing health concerns. Yurpeak is the second Eli Lilly tirzepatide brand to enter the Indian market, following DCGI approval for its use.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is used alongside diet and exercise for adults with obesity (BMI ≥ 30). It is also for overweight individuals (BMI ≥ 27) with a related health condition and patients with type 2 diabetes.

Yurpeak will be available in six strengths (2.5 mg to 15 mg) via the KwikPen device for easy, precise dosing. Cipla will distribute and promote the therapy in India. Meanwhile, Lilly will manufacture and supply it at the same price as Mounjaro.

Achin Gupta, Global COO of Cipla, said the launch is a major step in tackling obesity and type 2 diabetes. He highlighted the company’s focus on accessibility and patient awareness.

Cipla will also provide guidance on dosing, self-injection, and safe use to help patients manage the treatment effectively.

At 3:30 PM, shares of Cipla ended 1.42% higher at Rs 1,512 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!